APPTT
CLIN
Don Sanders, MD
Pediatrics
Riley Hospital for Children at Indiana University Health
Jennifer Guimbellot, MD, PhD
Pediatrics
Arkansas Children's Hospital/Arkansas Children's Research Institute
In the era of highly effective modulator therapy, the cystic fibrosis community continues to need biomarkers and outcome measures to accurately guide personalized treatments and improve long-term outcomes, as well as further develop new therapies for those who are ineligible or poorly responsive to currently available therapies. Attendees at this session will learn about novel research on known measures, such as sweat chloride and spirometry, as well as new predictive tools, monitoring strategies, and innovative approaches to measuring disease severity and response to interventions.